Chapter 3. Interpreting Clinical Evidence

  1. Nick Freemantle1 and
  2. Suzanne Hill2
  1. Nick Freemantle,
  2. Joanne Eastaugh,
  3. Melanie Calvert,
  4. Suzanne Hill and
  5. Jesse Berlin

Published Online: 5 NOV 2007

DOI: 10.1002/9780470994719.ch3

Evaluating Pharmaceuticals for Health Policy and Reimbursement

Evaluating Pharmaceuticals for Health Policy and Reimbursement

How to Cite

Freemantle, N., Eastaugh, J., Calvert, M., Hill, S. and Berlin, J. (2004) Interpreting Clinical Evidence, in Evaluating Pharmaceuticals for Health Policy and Reimbursement (eds N. Freemantle and S. Hill), Blackwell Science Ltd, Oxford, UK. doi: 10.1002/9780470994719.ch3

Editor Information

  1. 1

    Department of Primary Care and General Practice, University of Birmingham,Birmingham,UK

  2. 2

    Faculty of Health,University of Newcastle,Newcastle, Australia

Publication History

  1. Published Online: 5 NOV 2007
  2. Published Print: 1 AUG 2004

ISBN Information

Print ISBN: 9780727917843

Online ISBN: 9780470994719

SEARCH

Keywords:

  • randomise trials;
  • meta-analysis;
  • coronary heart disease;
  • clinical trials;
  • equivalence margins

Summary

This chapter contains sections titled:

  • Introduction

  • Randomised trials

  • Meta-analysis of multiple trials

  • Indirect comparisons

  • Composite outcomes

  • Equivalence and noninferiority issues in clinical trials

  • Equivalence margins

  • Surrogate outcomes

  • Sponsorship of studies

  • Are industry funded trials biased?

  • Are industry funded trials of poorer quality?

  • What features of trials may lead to positive results and pro-industry outcomes?

  • Trial reporting and metrics

  • Relative versus absolute differences

  • Conclusion

  • References